The Patient Engagement Layer for Life Sciences
From clinical trial enrollment to post-market adherence. Conversational AI infrastructure that reaches patients across the entire drug lifecycle — trials, launch, and beyond.
The Problem
Patients Exist. Reaching Them Is the Bottleneck.
In clinical trials, 80% of studies fail to enroll on time — not because eligible patients don't exist, but because you can't reach them. After launch, pharma spends $5 billion annually on patient support programs, yet only 3-8% of eligible patients ever use them. The infrastructure to connect with patients at scale simply doesn't exist.
- Trials Delayed
- 80%
- PSP Utilization
- 3-8%
- Script Abandonment
- 20-30%
Clinical Trials
Accelerate Enrollment. Improve Retention.
80% of trials fail to meet enrollment timelines. Delays cost $600K-$8M per day. The infrastructure to reach patients changes that equation.
- Pre-Screening at Scale
- Reach thousands of potential participants with conversational pre-screening. Identify eligible candidates before sites spend coordinator time on unqualified prospects.
- Enrollment Coordination
- Schedule site visits. Coordinate travel logistics. Send reminders. Answer questions. AI handles the coordination so sites focus on the science.
- Multi-Site Orchestration
- 10 sites. 5 countries. Different languages. Different regulations. One platform that coordinates patient engagement across your entire trial footprint.
- Retention Engagement
- Trial participation is a commitment. Regular check-ins, visit reminders, and concern resolution. Reduce dropout by maintaining meaningful patient connection.
- Decentralized Trial Support
- Hybrid and decentralized trials need patient engagement at home. Coordinate remote visits, home health, and device logistics through natural conversation.
- Site Enablement
- Give coordinators pre-screened, interested candidates — not cold lists. Sites focus on clinical work instead of phone tag.
Patient Support Programs
Pharma Spends $5B on Programs Patients Never Use
You invest in patient support programs — copay assistance, nurse educators, adherence support, specialty pharmacy coordination. But only 3-8% of eligible patients ever enroll. Why? They simply don't know these services exist.
Rivvi changes that equation. Proactive outreach reaches patients at the moment of prescription. Natural conversation explains available support. Enrollment happens during the call, not through abandoned web forms.
The result: patients who need support actually receive it. Program utilization increases. Adherence improves. The investment in patient services finally pays off.
- Program Enrollment Proactive outreach at prescription
- Benefits Navigation Prior auth and copay coordination
- Ongoing Engagement Adherence support throughout therapy
Hub Services
The Conversational Layer for Specialty Pharmacy
Specialty medications require complex coordination. Benefits investigation, prior authorization, patient onboarding — all require patient engagement. Most hub services rely on inbound calls. Rivvi makes them proactive.
- Therapy Initiation
- New specialty prescription? Patients receive immediate outreach explaining the medication, answering questions, and coordinating first fill. No waiting for patients to call in.
- Benefits Coordination
- Prior authorization required? Keep patients informed throughout the process. When approval comes through, coordinate pickup immediately. No patients lost to administrative delays.
- Adherence Engagement
- High-cost specialty medications require consistent adherence. Regular check-ins surface barriers early — cost concerns, side effects, confusion — before they become abandonments.
- Refill Coordination
- Specialty refills often require coordination — shipping schedules, temperature requirements, patient availability. AI handles the logistics so patients stay on therapy.
Real-World Evidence
Collect Patient Experience Data Through Conversation
FDA increasingly accepts real-world evidence for regulatory decisions. The challenge is collecting it.
Traditional RWE collection relies on claims data and chart reviews — retrospective, incomplete, and disconnected from patient experience. Patient-reported outcomes require surveys that patients ignore or abandon.
Conversational engagement changes the equation. Natural dialogue surfaces treatment experiences, symptom patterns, and quality of life insights that structured surveys miss. Patients share what they're actually experiencing, not what a form asks them to report.
The result: richer patient experience data collected at scale, with higher completion rates than traditional PRO instruments. Evidence that supports regulatory submissions, label expansions, and market access negotiations.
- Patient-Reported Outcomes Collected through natural conversation
- Treatment Experience Real-world effectiveness signals
- Safety Surveillance Early adverse event detection
Post-Market Adherence
20-30% of Patients Abandon Prescriptions
After all the investment in R&D, regulatory approval, and launch — patients don't take the medication. Proactive engagement changes that.
New-to-Therapy Engagement
Barrier Identification
Refill Coordination
Patient Assistance Connection
Why Trials Actually Enroll
From Cold Outreach to Warm Engagement
Traditional Recruitment
- ✗Cold calls to patient lists
- ✗Form letters and email blasts
- ✗Sites doing phone tag instead of science
- ✗Patients don't understand the trial
Conversational Engagement
- Natural dialogue that answers questions
- Concerns addressed in real time
- Sites receive prepared, interested candidates
- Patients understand before they enroll
From Manual Coordination to Automated Workflows
Traditional Coordination
- ✗Coordinators playing phone tag
- ✗Missed visits and dropouts
- ✗No visibility into patient barriers
- ✗Retention is reactive
Platform Orchestration
- Visit scheduling through conversation
- Proactive reminders and check-ins
- Barriers surfaced and addressed early
- Retention is systematic
The Stakes
What Trial Delays Actually Cost
- 80%
- Trials Delayed
- fail enrollment timelines
- $600K-8M
- Daily Cost
- per day of delay
- 37%
- Site Under-Enrollment
- of sites miss targets
- 11%
- Zero Enrollment
- of sites enroll no one
Partnership
Powering Global Clinical Trial Networks
Rivvi partners with leading clinical trial and patient services organizations to deliver patient engagement at global scale.
Our partnership with MassiveBio brings AI-powered patient engagement to oncology clinical trials across 26+ pharmaceutical company programs. Patients get matched to trials faster. Sites receive prepared candidates. Enrollment timelines compress.
This infrastructure approach — powering existing networks rather than competing with them — means your organization gets proven technology without building from scratch. Deploy in weeks, not years.
- Global Reach Multi-country, multi-language support
- Oncology Expertise Specialized for complex trial coordination
- Proven Scale Supporting 26+ pharma programs
How It Works
From Patient Data to Engaged Patients
Provide your patient population — from trial databases, hub enrollment lists, prescription data, or referral networks. The platform conducts conversational outreach at scale.
Natural dialogue engages patients. Questions answered. Barriers identified. Interested patients scheduled or enrolled. Throughout therapy, ongoing engagement maintains connection.
Your team sees actionable intelligence: enrolled patients, identified barriers, scheduled appointments, completed workflows. Not call logs. Results.
- Any Patient Source Trial lists, hub data, Rx feeds
- Conversational Engagement Natural dialogue, not robocalls
- Actionable Outcomes Enrolled patients, not just calls made
See Patient Engagement Infrastructure in Action
30-minute walkthrough with our team. Bring your hardest patient engagement challenge — trial enrollment, PSP utilization, specialty adherence. We'll show you what the platform can do.